The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
Open accessAbstract
Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its increasing global prevalence and because chronic hyperglycemic states are closely linked with obesity, liver disease and several cardiovascular diseases. Since the early discovery of insulin, numerous antihyperglycemic drug therapies to treat diabetes have been approved, and also discontinued, by the United States Food and Drug Administration (FDA). To provide an up-to-date account of the current trends of antidiabetic pharmaceuticals, this review offers a comprehensive analysis of the main classes of antihyperglycemic compounds and their mechanisms: insulin types, biguanides, sulfonylureas, meglitinides (glinides), alpha-glucosidase inhibitors (AGIs), thiazolidinediones (TZD), incretin-dependent therapies, sodium-glucose cotransporter type 2 (SGLT2) inhibitors and combinations thereof. The number of therapeutic alternatives to treat T2DM are increasing and now there are nearly 60 drugs approved by the FDA. Beyond this there are nearly 100 additional antidiabetic agents being evaluated in clinical trials. In addition to the standard treatments of insulin therapy and metformin, there are new drug combinations, e.g., containing metformin, SGLT2 inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors, that have gained substantial use during the last decade. Furthermore, there are several interesting alternatives, such as lobeglitazone, efpeglenatide and tirzepatide, in ongoing clinical trials. Modern drugs, such as glucagon-like peptide-1 (GLP-1) receptor agonists, DPP4 inhibitors and SGLT2 inhibitors have gained popularity on the pharmaceutical market, while less expensive over the counter alternatives are increasing in developing economies. The large heterogeneity of T2DM is also creating a push towards more personalized and accessible treatments. We describe several interesting alternatives in ongoing clinical trials, which may help to achieve this in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Self-citationThe mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
Diabetes mellitus: The epidemic of the century
Kharroubi, A. T. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.850 · Cited by 1,229
Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
Chawla, R., Chawla, A., & Jaggi, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183480 · Cited by 1,106
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Self-citationAMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 754
Sivitz, W. I., & Yorek, M. A. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2531 · Cited by 742
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Yu, J. G., Javorschi, S., Hevener, A. L., Kruszynska, Y. T., Norman, R. A., Sinha, M., & Olefsky, J. M. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2968 · Cited by 725
Managing diabetes with nanomedicine: challenges and opportunities
Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G., & Langer, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4477 · Cited by 613
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
SGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
State of the art paper Sulfonylureas and their use in clinical practice
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.53304 · Cited by 514
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK
Wang, Y., An, H., Liu, T., Qin, C., Sesaki, H., Guo, S., Radovick, S., Hussain, M., Maheshwari, A., Wondisford, F. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.070 · Cited by 432 · cited 2×
“This results in decreased plasma glucose and lactate levels, reduced liver gluconeogenesis, hepatic glucose secretion, and endogenous glucose production (Foretz et al., 2014; Rena et al., 2017; Wang et al., 2019).”
BackgroundAMPK activation: a therapeutic target for type 2 diabetes?
Saha, A., Coughlan, K., Valentine, R., & Ruderman, N. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s43731 · Cited by 429
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418
Thiazolidinediones: the forgotten diabetes medications
Lebovitz, H. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1270-y · Cited by 388
Hu, C., & Jia, W. (2018) · Diabetes · doi:10.2337/dbi17-0013 · Cited by 386
SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment
Wu, C.-T., Lidsky, P. V., Xiao, Y., Lee, I. T., Cheng, R., Nakayama, T., Jiang, S., Demeter, J., Bevacqua, R. J., Chang, C. A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.05.013 · Cited by 364
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018) · Nature Medicine · doi:10.1038/s41591-018-0159-7 · Cited by 313
Seven evolutionarily conserved human rhodopsin G protein‐coupled receptors lacking close relatives
Fredriksson, R., Höglund, P. J., Gloriam, D. E. I., Lagerström, M. C., & Schiöth, H. B. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01196-7 · Cited by 292
Self-citationRask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Self-citationTherapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity
Overton, H. A., Fyfe, M. C. T., & Reynet, C. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707529 · Cited by 264
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., & Tan, G. D. (2016) · Diabetes Care · doi:10.2337/dc16-0650 · Cited by 262
Ahmad, Z., Banerjee, P., Hamon, S., Chan, K.-C., Bouzelmat, A., Sasiela, W. J., Pordy, R., Mellis, S., Dansky, H., Gipe, D. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039107 · Cited by 246
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.023 · Cited by 211
Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
Inhibitory Effect of α-Glucosidase Inhibitors Varies According to Its Origin
Oki, T., Matsui, T., & Osajima, Y. (1999) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf980788t · Cited by 209
Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa, B. C., & Inzucchi, S. E. (2018) · Diabetologia · doi:10.1007/s00125-018-4663-6 · Cited by 190
Fructose: A Key Factor in the Development of Metabolic Syndrome and Hypertension
Khitan, Z., & Kim, D. H. (2013) · Journal of Nutrition and Metabolism · doi:10.1155/2013/682673 · Cited by 180
Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report
Hollstein, T., Schulte, D. M., Schulz, J., Glück, A., Ziegler, A. G., Bonifacio, E., Wendorff, M., Franke, A., Schreiber, S., Bornstein, S. R., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00281-8 · Cited by 176
Mechanisms of the Glycaemic Effects of Sulfonylureas
Ashcroft, F. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979837 · Cited by 166
Guardado‐Mendoza, R., Prioletta, A., Jiménez-Ceja, L. M., Sosale, A., & Folli, F. B. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.34991 · Cited by 153
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 145
Insulin Resistance, Type 1 and Type 2 Diabetes, and Related Complications 2017
Ndisang, J. F., Vannacci, A., & Rastogi, S. (2017) · Journal of Diabetes Research · doi:10.1155/2017/1478294 · Cited by 134
Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
Toulis, K. A., Nirantharakumar, K., Pourzitaki, C., Barnett, A. H., & Tahrani, A. A. (2020) · Drugs · doi:10.1007/s40265-020-01278-z · Cited by 128
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · PubMed · Cited by 126
Saponaro, F., Sestito, S., Runfola, M., Rapposelli, S., & Chiellini, G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00331 · Cited by 124
Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017
Wilkinson, S., Douglas, I., Stirnadel-Farrant, H. A., Fogarty, D. G., Pokrajac, A., Smeeth, L. L., & Tomlinson, L. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022768 · Cited by 120
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120
Self-citationRitter, K., Buning, C., Halland, N., Pöverlein, C., & Schwink, L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01198 · Cited by 118
O’Brien, M. J., Karam, S., Wallia, A., Kang, R. H., Cooper, A., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 118
Type 1 diabetes onset triggered by COVID-19
Marchand, L., Pecquet, M., & Luyton, C. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01570-0 · Cited by 116
Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 115
Diabesity and antidiabetic drugs
Pappachan, J. M., Fernandez, C. J., & Chacko, E. C. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.10.004 · Cited by 108
GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
Matschinsky, F. (2013) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.007 · Cited by 106
Gourgari, E., Wilhelm, E. E., Hassanzadeh, H. R., Aroda, V. R., & Shoulson, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.005 · Cited by 98
History of current non-insulin medications for diabetes mellitus
Quianzon, C. C. L., & Cheikh, I. E. (2012) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v2i3.19081 · Cited by 96
Mohan, V., Khunti, K., Chan, S. P., Filho, F. F., Tran, N. Q., Ramaiya, K. L., Joshi, S., Mithal, A., Mbaye, M. N., Nicodemus, N. A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00733-9 · Cited by 95
Lin, Y., & Sun, Z. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01056.x · Cited by 91
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 90
Kohro, T., Yamazaki, T., Sato, H., Harada, K., Ohe, K., Komuro, I., & Nagai, R. (2013) · International Heart Journal · doi:10.1536/ihj.54.93 · Cited by 88
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
Scheen, A. J., Paquot, N., & Lefèbvre, P. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395020 · Cited by 88
New and emerging drugs and targets for type 2 diabetes: reviewing the evidence.
Miller, B. R., Nguyen, H. T., Hu, C. J.-H., Lin, C., & Nguyen, Q. P. H. (2014) · PubMed · Cited by 86
Liu, R., Wang, H., Xu, B., Chen, W., Turlova, E., Dong, N., Sun, C. L. F., Lu, Y., Fu, H., Shi, R., et al. (2016) · Diabetes · doi:10.2337/db15-1737 · Cited by 80
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Kulzer, B., Daenschel, W., Daenschel, I., Schramm, W., Messinger, D., Weissmann, J., Vesper, I., Parkin, C. G., & Heinemann, L. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.09.002 · Cited by 77
Zhang, L., Chen, Q., Li, L., Kwong, J. S. W., Jia, P., Zhao, P., Wang, W., Zhou, X., Zhang, M., & Sun, X. (2016) · Scientific Reports · doi:10.1038/srep32649 · Cited by 75
Tian, Y., Johnson, G., & Ashcroft, S. J. H. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1722 · Cited by 72
Bugliani, M., Syed, F., de Paula, F. M. M., Omar, B. A., Suleiman, M., Mossuto, S., Grano, F., Cardarelli, F., Boggi, U., Vistoli, F., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.019 · Cited by 69
Orphan Drugs and Their Impact on Pharmaceutical Development
Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.003 · Cited by 69
Self-citationSingla, R., Bindra, J., Singla, A., Gupta, Y., & Kalra, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_646_18 · Cited by 69
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Mirabelli, M., CHIEFARI, E. D., Puccio, L., FOTI, D. P., & Brunetti, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103664 · Cited by 69
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
Irons, B. K., & Minze, M. G. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38753 · Cited by 68
Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
Lupo, M. G., & Ferri, N. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030039 · Cited by 67
Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity
Joharapurkar, A. A., Jain, M. R., & Dhanesha, N. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s56924 · Cited by 63
Chun, E., Han, C. K., Yoon, J. H., Sim, T. B., Kim, Y., & Lee, K. (2004) · International Journal of Cancer · doi:10.1002/ijc.20687 · Cited by 62
Kim, H., Kim, D. M., Cha, B., Park, T. S., Kim, K., Kim, D., Chung, C. H., Park, J., Jang, H. C., & Choi, D.-S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12201 · Cited by 60
Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
Christopoulou, E. C., Elisaf, M., & Filippatos, T. D. (2019) · Disease Markers · doi:10.1155/2019/6578327 · Cited by 58
Zhao, W., Yang, S., Chen, J., Zhao, J., & Dong, J. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.009 · Cited by 52
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Wang, X., Zheng, P., Huang, G., Yang, L., & Zhou, Z. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0519-0 · Cited by 51
GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
Kang, S.-U. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.011 · Cited by 49
A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors
Lau, J., Rousseau, J., Kwon, D., Bénard, F., & Lin, K. (2020) · Pharmaceuticals · doi:10.3390/ph13080199 · Cited by 48
Ochman, A. R., Lipinski, C. A., Handler, J. A., Reaume, A. G., & Saporito, M. S. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192187 · Cited by 46
Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
Kramer, C. K., Ye, C., Campbell, S., & Retnakaran, R. R. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.021 · Cited by 46
Del Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
ANGPTL3: a novel biomarker and promising therapeutic target
Jiang, S., Qiu, G.-H., Zhu, N., Hu, Z., Liao, D., & Li, Q. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1566342 · Cited by 41
Lu, D., Dopart, R., & Kendall, D. A. (2015) · Cell Stress and Chaperones · doi:10.1007/s12192-015-0653-5 · Cited by 40
Intracellular targets for antidiabetic sulfonylureas and potassium channel openers
Szewczyk, A. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00136-6 · Cited by 39
Saporito, M. S., Ochman, A. R., Lipinski, C. A., Handler, J. A., & Reaume, A. G. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192096 · Cited by 39
Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061
Burkey, B. F., Hoglen, N. C., Inskeep, P. B., Wyman, M. A., Hughes, T. E., & Vath, J. E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246272 · Cited by 39
Eldor, R., Neutel, J., Homer, K. E., & Kidron, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14499 · Cited by 39
Morgen, M., Jöst, C., Malz, M., Janowski, R., Niessing, D., Klein, C. D. P., Gunkel, N., & Miller, A. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00755 · Cited by 38
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.07.004 · Cited by 33
11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study
Shukla, R. K. G., Basu, A. K., Mandal, B., Mukhopadhyay, P., Maity, A., Chakraborty, S., & Devrabhai, P. K. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0344-9 · Cited by 30
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
Lang, W. R., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000258 · Cited by 29
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes
Yoon, K., Kang, J., Kwon, S. C., TRAUTMANN, M. E., Hompesch, M., Stewart, J. A., & SORLI, C. H. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14032 · Cited by 29
Yamamoto‐Honda, R., Takahashi, Y., Mori, Y., Yamashita, S., Yoshida, Y., Kawazu, S., Iwamoto, Y., Kajio, H., Yanai, H., Mishima, S., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9481-17 · Cited by 28
A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
Chikara, G., Sharma, P. K., Dwivedi, P., Charan, J., Ambwani, S. R., & Singh, S. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0668-z · Cited by 25
The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
Pop, L. M., & Lingvay, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0954-4 · Cited by 25
Taira, M., Takasu, N., Komiya, I., Taira, T., & Tanaka, H. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80005-0 · Cited by 24
Wu, P., Wu, V., Lin, C., Pan, C., Chen, C.-Y., Huang, T., Wu, C., Chen, L., & Wu, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17475 · Cited by 24
Zambad, S. P., Munshi, Dubey, Gupta, Busiello, Lanni, A., Goglia, F., Gupta, Chauthaiwale, & Dutt, C. (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s15323 · Cited by 23
Pharmacogenetics of Antidiabetic Drugs
Srinivasan, S., Yee, S. W., & Giacomini, K. M. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.005 · Cited by 23
SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
Ito, H., Shinozaki, M., Nishio, S., & Abe, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232395 · Cited by 22
Ramzan, S., Timmins, P., Hasan, S. S., & Babar, Z. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.05.009 · Cited by 22
Al-Omary, F. A. M. (2017) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/bs.podrm.2017.02.003 · Cited by 22
A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
Khalse, M., & Bhargava, A. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_104_18 · Cited by 21
Kolodka, T. M., Charles, M. L., Raghavan, A., Radichev, I., Amatya, C., Ellefson, J., Savinov, A. Y., Nag, A., Williams, M. S., & Robbins, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103981 · Cited by 20
Hong, D. J., Jung, S. H., Kim, J., Jung, D., Ahn, Y., Suh, K. H., & Min, K. H. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1693555 · Cited by 19
Secrest, M. H., Azoulay, L., Dahl, M. E., Clemens, K. K., Durand, M., Hu, N., Targownik, L. E., Turin, T. C., Dormuth, C. R., & Filion, K. B. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4878 · Cited by 16
Jiang, S., Wu, X., Wang, Y., Zou, J., & Zhao, X. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173272 · Cited by 16
Sulis, P. M., Dambrós, B. F., Mascarello, A., Santos, A. R. S., Yunes, R. A., Nunes, R. J., Frederico, M. J. S., & Silva, F. R. M. B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27680 · Cited by 15
A MetAP2 inhibitor blocks adipogenesis, yet improves glucose uptake in cells
Siddik, M. A. B., Das, B. C., Weiss, L. M., Dhurandhar, N. V., & Hegde, V. K. (2019) · Adipocyte · doi:10.1080/21623945.2019.1636627 · Cited by 14
Wentworth, J. M., Colman, P. G., & Zafgen Study Group (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14009 · Cited by 14
Giorda, C. B., Orsi, E., Cosmo, S. D., Bossi, A. C., Guerzoni, C., Cercone, S., Gilio, B., & Cavalot, F. L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00871-5 · Cited by 9
Trask, L. E., Kasid, N., Homa, K. A., & Chaidarun, S. (2013) · Endocrine Practice · doi:10.4158/ep12327.or · Cited by 7
van den Boom, L., Kaiser, M., & Kostev, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14338 · Cited by 7
Orphan Drugs and Their Impact on Pharmaceutical Development
Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.09.007 · Cited by 1
Self-citation
Cited by
Chiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Despite the numerous anti-hyperglycemic agents that are already available on the market for T2DM treatment, there are still a surprising number of drug candidates in clinical trials, of which no less than 40% are with novel therapeutic molecules or targets [144,145].”
Background
Metadata
- Authors
- Dahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-19
- Volume
- 12
- Pages
- 807548-807548
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4205946014
- Cited by
- 275
- References
- 132
- FWCI
- 36.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.